Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in August: 2022 Wedbush

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 19, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, August 2, 2022 at 8:00 a.m.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in June: Jefferies

Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints Zuranolone 50 mg was generally well-tolerated and demonstrated a safety profile consistent with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on

Rolling NDA submission for zuranolone in MDD underway, with full submission expected to be completed in the second half of 2022, associated NDA submission in PPD planned for early 2023 Topline data from Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD on track for mid-2022 Six planned and

The companies expect to complete submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression anticipated in the first half of 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 19, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 3, 2022 at 8:00 a.m.

Data to be Presented During the Emerging Science Session at the American Academy of Neurology’s 74th Annual Meeting The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild